The clinical efficacy and safety of transurthral electrovaporization of the prostate (TUVP) for benign prostatic hyperplasia( BPH) at high risk

VernacularTitle:经尿道前列腺汽化电切术治疗高危前列腺增生症的疗效观察
Author: Xudong LI ; Guanjie SONG ; Yanhua CHANG
Publication Type:Journal Article
Keywords: Prostatic hyperplasia; Transurethral electrovaporization of prostate
From: Chinese Journal of Primary Medicine and Pharmacy 2011;18(12):1602-1603
CountryChina
Language:Chinese
Abstract: Objective To investigate the clinical efficacy and safety of transurthral electrovaporization of the prostate(TUVP) for benign prostatic hyperplasia( BPH) at high risk.Methods Forty-eight patients with BPH at high risk were treated with transurthral electrovaporization of the prostate(TUVP).The clinical data and therapeutic results were measured.Results All patients went through the perioperiative period safely and had been followed up for 3 to 14 months.Postvoid residual ( PVR) , the International Prostate Symptom Score (IPSS) and quality of life (QOL) before operations were (97.5 ± 16.9) ml, ( 28.4 ± 2.3 ) score and (5.5 ±0.6) score respectively.Three months after operation ,PVR ,IPSS and QOL were( 30.2 ± 12.3 ) ml, (8.2 ± 1.3 ) score and( 1.9 ±0.5) score respectively,there was significant difference between them(t =22.31,53.16,31.94,all P<0.05).Conclusion TUVP is an effective and safe method in treating BPH patients at high risk.